Skip to main content

What the FDA labels say about taking them together

Pioglitazone and teriflunomide

Teriflunomide's FDA label of February 20, 2026 names pioglitazone in its drug interactions section; the pioglitazone label PlainMeds reads does not name teriflunomide. The teriflunomide label: “In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 may be increased.”

Check it at the source: the pioglitazone FDA label on DailyMed (effective March 28, 2025, Takeda Pharmaceuticals America, Inc.); the teriflunomide FDA label on DailyMed (effective February 20, 2026, Genzyme Corporation).

What does the pioglitazone label say about teriflunomide?

Pioglitazone's label (effective March 28, 2025) does not name teriflunomide in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Actos), Takeda Pharmaceuticals America, Inc., effective March 28, 2025 (SPL set d2ddc491-88a9-4063-9150-443b4fa4330c), via openFDA; the full label on DailyMed

What does the teriflunomide label say about pioglitazone?

Teriflunomide label, drug interactions

In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased.

Source: FDA drug label (Aubagio), NDA202992 (Sanofi Aventis Us), as published by Genzyme Corporation, effective February 20, 2026 (SPL set 4650d12c-b9c8-4525-b07f-a2d773eca155), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

22Pioglitazone generic labelers
15Teriflunomide generic labelers
PioglitazoneTeriflunomide
Labeled forType 2 diabetesMultiple sclerosis
Boxed warningYesYes
Pharmacy cost (NADAC)$0.0675 per tablet 15 mg tablet$0.233 per tablet 14 mg tablet
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?